Trials / Completed
CompletedNCT05059197
Efficacy and Safety of AP Collagen Peptide on the Skin
Evaluation of Skin Health Improvement and Safety in AP Collagen Peptide: Randomized, Double-blind, Placebo-controlled
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 54 (actual)
- Sponsor
- Amorepacific Corporation · Industry
- Sex
- All
- Age
- 35 Years – 60 Years
- Healthy volunteers
- Accepted
Summary
This double-blinded, randomized, placebo-controlled study aimed to evaluate the efficacy and safety of AP collagen peptides (APCP) containing 3% Glycine-Proline-Hydroxyproline (GPH) on improving skin health. Subjects with dried skin were randomly assigned to receive placebo or APCP once daily for 12 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | AP collagen peptide | Health functional food |
| DIETARY_SUPPLEMENT | Placebo | placebo |
Timeline
- Start date
- 2020-12-15
- Primary completion
- 2021-09-30
- Completion
- 2021-10-12
- First posted
- 2021-09-28
- Last updated
- 2021-11-11
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT05059197. Inclusion in this directory is not an endorsement.